Literature DB >> 30325326

Immunoglobulin E and bullous pemphigoid.

Emanuele Cozzani1, Giulia Gasparini1, Giovanni Di Zenzo2, Aurora Parodi1.   

Abstract

Clinical features and histological findings in bullous pemphigoid (BP) suggest a Th2-oriented inflammatory reaction, especially in the early stages of the disease. Elevated total serum IgE levels, blood eosinophilia, and elevated serum levels of different soluble inflammatory Th2 response mediators have been described in large cohorts of patients with classic clear-cut BP manifestations. Direct immunofluorescence, indirect immunofluorescence, and anti-BP230 and anti-BP180 IgE ELISA testing show self-reactive IgE autoantibodies in a consistent number of BP patients. Both IgE autoantibodies and a Th2-oriented immune response may play a role in the initial phases of BP and atypical cases of BP, such as severe erythematous and urticarial forms of BP, as well as blister formation. Two recently reported experimental murine models employing IgE autoantibodies against BP180 have been reported and the successful treatment of bullous pemphigoid with the anti-IgE antibody, omalizumab, supports the roles played by IgE autoantibodies in BP pathogenesis.

Entities:  

Keywords:  Th2; anti-BP230 and anti-BP180 IgE; bullous pemphigoid; omalizumab

Mesh:

Substances:

Year:  2018        PMID: 30325326     DOI: 10.1684/ejd.2018.3366

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  13 in total

Review 1.  Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?

Authors:  Roberto Russo; Niccolò Capurro; Emanuele Cozzani; Aurora Parodi
Journal:  J Clin Med       Date:  2022-06-12       Impact factor: 4.964

2.  Bullous pemphigoid and milia: prevalence and clinical laboratory findings in a Brazilian sample.

Authors:  Sebastián Vernal; Ederson Valei de Oliveira; Roberto Bueno Filho; Tamiris A Julio; Eduardo A Donadi; Aline Turatti; Norito Ishii; Takashi Hashimoto; Ana Maria Roselino
Journal:  An Bras Dermatol       Date:  2022-05-27       Impact factor: 2.113

Review 3.  Coagulation and Skin Autoimmunity.

Authors:  Massimo Cugno; Alessandro Borghi; Simone Garcovich; Angelo Valerio Marzano
Journal:  Front Immunol       Date:  2019-06-20       Impact factor: 7.561

Review 4.  The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.

Authors:  Kelly N Messingham; Tyler P Crowe; Janet A Fairley
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

5.  Blister Fluid Induces MMP-9-Associated M2-Type Macrophages in Bullous Pemphigoid.

Authors:  Meriem Riani; Céline Muller; Camille Bour; Philippe Bernard; Frank Antonicelli; Sébastien Le Jan
Journal:  Front Immunol       Date:  2019-08-07       Impact factor: 7.561

Review 6.  New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update.

Authors:  Giovanni Genovese; Giovanni Di Zenzo; Emanuele Cozzani; Emilio Berti; Massimo Cugno; Angelo Valerio Marzano
Journal:  Front Immunol       Date:  2019-07-02       Impact factor: 7.561

7.  Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.

Authors:  S Morteza Seyed Jafari; Karolina Gadaldi; Laurence Feldmeyer; Nikhil Yawalkar; Luca Borradori; Christoph Schlapbach
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

8.  IL-13 Genetic Susceptibility to Bullous Pemphigoid: A Potential Target for Treatment and a Prognostic Marker.

Authors:  Yiman Wang; Xuming Mao; Yangchun Liu; Yuyan Yang; Hongzhong Jin; Li Li
Journal:  Front Immunol       Date:  2022-01-24       Impact factor: 7.561

9.  Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?

Authors:  Roberto Russo; Emanuele Cozzani; Giulia Gasparini; Aurora Parodi
Journal:  Dermatol Ther       Date:  2020-01-02       Impact factor: 2.851

Review 10.  Pruritus as a Distinctive Feature of Type 2 Inflammation.

Authors:  Simone Garcovich; Martina Maurelli; Paolo Gisondi; Ketty Peris; Gil Yosipovitch; Giampiero Girolomoni
Journal:  Vaccines (Basel)       Date:  2021-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.